Companies / BOC Sciences / Abituzumab
BOC Sciences

Abituzumab | BOC Sciences

Abituzumab is a humanized anti-integrin _V monoclonal antibody developed for the treatment of prostate cancer metastatic. Abituzumab binds to _V_3 and inhibits endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in _V_3-expressing tumor cells.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.